替吉奥联合奈达铂治疗晚期肺鳞癌的疗效分析

Efficacy of S-1 combined with nedaplatin in advanced lung squamous carcinoma

目的探讨替吉奥联合奈达铂治疗晚期肺鳞癌的临床疗效。方法收集2013年6月至2014年12月41例晚期肺鳞癌患者的临床资料，所有患者均采用替吉奥联合奈达铂治疗，回顾性分析其治疗效果。结果41例患者中，完全缓解（CR）0例，部分缓解（PR）12例（29．27％），稳定（SD）19例（46．34％），进展（PD）10例（24．39％），疾病控制率为75．61％，中位无进展生存期为7．2个月。不良反应主要为骨髓抑制，还有轻度胃肠道反应、厌食、疲倦等，给予对症治疗后均可缓解。结论替吉奥联合奈达铂治疗晚期肺鳞癌疗效较好，不良反应可以耐受，安全性良好，值得临床推广和进一步观察。

Objective To investigate the clinical efficacy of tegafur gimeracil oteracil potassium capsule （S-1） combined with nedaplatin in advanced lung squamous carcinoma. Methods The clinical data of forty-one patients with advanced lung squamous carcinoma confirmed by pathology and imaging from June 2013 to December 2014 were selected. All patients S-1 were with combined with nedaplatin. The disease control rate, safety and progression-free survival were investigated. Results Among all the patients, there was no CR, 12 cases of PR, 19 cases of SD, 10 cases of PD ; the disease control rate was 75.61%, mPFS was 7.2 months. The major adverse event was myelosuppression, others were gastroin- testinal reactions, anorexia, fatigue and so on, which were all alleviated after treatment. Conclusions S-1 combined with nedaplatin shows good efficacy in treatment of advanced lung squamous carcinoma, and it is well tolerated, justifying its further study and potentially wider implementation in clinic.